Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.53 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | RAD52 | P43351 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 6/20 | 0.44 |
| ▸ | DGKA | P23743 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5512249 | 1.00 | NAAA (0.53) | NAAAHCAR2EPHX1TSHRRAD52 | |
| SCHEMBL5512033 | 1.00 | NAAA (0.53) | NAAAHCAR2EPHX1TSHRRAD52 | |
| SCHEMBL5514096 | 1.00 | NAAA (0.53) | NAAAHCAR2EPHX1TSHRRAD52 | |
| SCHEMBL5506856 | 1.00 | NAAA (0.53) | NAAAHCAR2EPHX1TSHRRAD52 | |
| SCHEMBL5517476 | 1.00 | NAAA (0.53) | NAAAHCAR2EPHX1TSHRRAD52 | |
| SCHEMBL5510321 | 1.00 | NAAA (0.53) | NAAAHCAR2EPHX1TSHRRAD52 | |
| SCHEMBL450585 | 1.00 | NAAA (0.53) | NAAAHCAR2EPHX1TSHRRAD52 | |
| SCHEMBL450736 | 0.98 | NAAA (0.50) | NAAAHCAR2EPHX1TSHRRAD52 | |
| SCHEMBL444270 | 0.92 | ATM (0.54) | NAAAHCAR2EPHX1TSHRNPSR1 | |
| SCHEMBL27841060 | 0.84 | NAAA (0.53) | NAAAHCAR2EPHX1TSHRRAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7157442-B2 | Antibacterial compound | SANKYO COMPANY, LIMITED (JP) | 2007-01-02 | — | — | US | disclosed |
| EP-1209166-B1 | NOVEL A-500359 DERIVATIVES | SANKYO CO (JP) | 2004-03-31 | — | — | EP | disclosed |
| US-20030171330-A1 | Antibacterial compound | SANKYO COMPANY, LIMITED (JP) | 2003-09-11 | — | — | US | disclosed |
| EP-1209166-A1 | NOVEL A-500359 DERIVATIVES | Sankyo Company, Limited (JP) | 2002-05-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171330-A1 | Antibacterial compound | TLR1, MPO, O60361 | NAAA 1397/4885HCAR2 2946/4885EPHX1 3783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.